Granted Patent
B2
US 12,383,512 · App. 17/777,681 · Granted Aug 12, 2025
Cannabidiol-type cannabinoid compound
Inventors:
Geoffrey Guy (Cambridge, GB); Volker Knappertz (Cambridge, GB); Benjamin Whalley (Cambridge, GB); Marie Woolley-Roberts (Cambridge, GB)
Assignee:
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.
Claims (10)
1. A method of treating epilepsy in a subject in need thereof, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of 6-hydroxy cannabidiol (6-OH CBD) as the only active ingredient.
2. The method of claim 1 , wherein the 6-OH CBD is in the form of a synthetic compound.
3. The method of claim 1 , wherein the 6-OH CBD is in the form of a pure or isolated compound.
4. The method of claim 1 , comprising administering a dose of 6-OH CBD that is less than 100 mg/kg/day to 1 mg/kg/day.
5. The method of claim 1 , comprising administering a dose of 6-OH CBD that is less than 100 mg/kg/day.
6. The method of claim 1 , wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients.
7. The method of claim 1 , wherein the subject is a mammal.
8. The method of claim 1 , wherein the subject is a human.
9. The method of claim 1 , wherein the subject is a dog.
10. The method of claim 1 , comprising administering a dose of 6-OH CBD that is from 1 mg/kg/day to about 250 mg/kg/day.
Assignments (3)
CHANGE OF NAME
Recorded May 1, 2025
From: GW RESEARCH LIMITED
To: JAZZ PHARMACEUTICALS RESEARCH UK LIMITED
Reel/Frame 071004/0029 →
SECURITY AGREEMENT
Recorded Jul 26, 2024
From: CAVION, INC.; CELATOR PHARMACEUTICALS, INC.; GW PHARMA LIMITED; JAZZ PHARMACEUTICALS, INC.; JAZZ PHARMACEUTICALS IRELAND LIMITED; JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (F/K/A GW RESEARCH LIMITED)
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 068173/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 23, 2022
From: GUY, GEOFFREY; KNAPPERTZ, VOLKER; WHALLEY, BENJAMIN; WOOLLEY-ROBERTS, MARIE
To: GW RESEARCH LIMITED
Reel/Frame 061200/0306 →
Priority Claims (1)
GB 1916974
· Nov 21, 2019
· national
Continuity (1)
References Cited (172)
US 6630507B1
· Hampson et al.
· 2003
[cited by applicant]
US 8632825B2
· Velasco Diez et al.
· 2014
[cited by applicant]
US 8790719B2
· Parolaro et al.
· 2014
[cited by applicant]
US 9017737B2
· Kikuchi et al.
· 2015
[cited by applicant]
US 9125859B2
· Whalley et al.
· 2015
[cited by applicant]
US 9474726B2
· Guy et al.
· 2016
[cited by applicant]
US 9949936B2
· Guy et al.
· 2018
[cited by applicant]
US 9949937B2
· Guy et al.
· 2018
[cited by applicant]
US 9956183B2
· Guy et al.
· 2018
[cited by applicant]
US 9956184B2
· Guy et al.
· 2018
[cited by applicant]
US 9956185B2
· Guy et al.
· 2018
[cited by applicant]
US 9956186B2
· Guy et al.
· 2018
[cited by applicant]
US 20170239193A1
· Guy et al.
· 2017
[cited by applicant]
US 20180071210A1
· Wilkhu et al.
· 2018
[cited by applicant]
US 20200138738A1
· Guy et al.
· 2020
[cited by applicant]
US 20200179303A1
· Guy et al.
· 2020
[cited by applicant]
US 20200206153A1
· Whalley et al.
· 2020
[cited by applicant]
US 20200352878A1
· Guy et al.
· 2020
[cited by applicant]
US 20210052512A1
· Guy et al.
· 2021
[cited by applicant]
US 20210059949A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210059976A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210169824A1
· Guy et al.
· 2021
[cited by applicant]
US 20210330636A1
· Guy et al.
· 2021
[cited by applicant]
US 20220008355A1
· Guy et al.
· 2022
[cited by applicant]
US 20220016048A1
· Guy et al.
· 2022
[cited by applicant]
US 20220023232A1
· Guy et al.
· 2022
[cited by applicant]
US 20220087951A1
· Knappertz
· 2022
[cited by applicant]
US 20220183997A1
· Guy et al.
· 2022
[cited by applicant]
US 20220184000A1
· Guy et al.
· 2022
[cited by applicant]
US 20220202738A1
· Guy et al.
· 2022
[cited by applicant]
US 20220211629A1
· Wilkhu et al.
· 2022
[cited by applicant]
US 20220226257A1
· Guy et al.
· 2022
[cited by applicant]
US 20220249396A1
· Guy et al.
· 2022
[cited by applicant]
US 20220257529A1
· Guy et al.
· 2022
[cited by applicant]
US 20220378714A1
· Guy et al.
· 2022
[cited by applicant]
US 20230032502A1
· Guy et al.
· 2023
[cited by applicant]
US 20230038423A1
· Silcock et al.
· 2023
[cited by applicant]
US 20230143812A1
· Knappertz et al.
· 2023
[cited by applicant]
US 20230277560A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277561A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277562A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230277563A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285419A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285420A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285421A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285422A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285423A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285424A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285426A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230285428A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230310464A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230346809A1
· Craig
· 2023
[cited by applicant]
US 20230372367A1
· Checketts et al.
· 2023
[cited by applicant]
US 20230372368A1
· Checketts et al.
· 2023
[cited by applicant]
US 20240016819A1
· Craig
· 2024
[cited by applicant]
US 20240025858A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240033229A1
· Guy et al.
· 2024
[cited by applicant]
US 20240033272A1
· Checketts et al.
· 2024
[cited by applicant]
US 20240050452A1
· Craig et al.
· 2024
[cited by applicant]
US 20240091241A1
· Guy et al.
· 2024
[cited by applicant]
US 20240130981A1
· Wilkhu
· 2024
[cited by applicant]
US 20240131041A1
· Tse
· 2024
[cited by applicant]
US 20240165048A1
· Guy
· 2024
[cited by applicant]
US 20240207220A1
· Guy et al.
· 2024
[cited by applicant]
US 20240215910A1
· Tse et al.
· 2024
[cited by applicant]
US 20240226032A9
· Wilkhu et al.
· 2024
[cited by applicant]
US 20240226123A9
· Tse
· 2024
[cited by applicant]
US 20240238218A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254066A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240254072A1
· Silcock et al.
· 2024
[cited by applicant]
US 20240261234A1
· Guy
· 2024
[cited by applicant]
WO WO2015193667A1
· 2015
[cited by applicant]
WO WO2015193668A1
· 2015
[cited by applicant]
WO WO2016094810A2
· 2016
[cited by applicant]
WO WO2016203239A1
· 2016
[cited by applicant]
WO WO2018061007A1
· 2018
[cited by applicant]
WO WO2018205022A1
· 2018
[cited by applicant]
Harvey, D. J., “Characterization of the Butyl Homologues of Delta1-tetrahydrocannabinol, Cannabinol and Cannabidiol in Samples of Cannabis by Combined Gas Chromatography and Mass Spectrometry,” J. Pharm. Pharmac., 28:28…
[cited by applicant]
Hill, T. D. M. et al., “Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB 1 receptor-independent mechanism,” British Journal of Pharmacology, 170(3):679-692 (2013).
[cited by applicant]
Morales, P. et al., “An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol,” Frontiers in Pharmacology, 8:422 (2017); doi:10.3389/fphar.2017.00422, 18 pages.
[cited by applicant]
Epidiolex® (cannabidiol) oral solution, CV, Prescribing Information, 2018, 30 pages; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf.
[cited by applicant]
Gaston, T. E. & Szaflarski, J. P., “Cannabis for the Treatment of Epilepsy: an Update,” Current Neurology and Neuroscience Reports, 18:73 (2018); doi:10.1007/s11910-018-0882-y.
[cited by applicant]
Kimball, A. W. et al., Chemical Protection against lonizing Radiation, Radiation Research, 7:1-12 (1957).
[cited by applicant]
Lander, N. et al., “Total Syntheses of Cannabidiol and A1-Tetrahydrocannabiinol Metabolites,” J Chem Soc Perkin 1, (1):8-16 (1976).
[cited by applicant]
Lewis, M. M. et al., Chemical Profiling of Medical Cannabis Extracts, ACS Omega, 2:6091-6103 (2017).
[cited by applicant]
Litchfield, J. T. & Wilcoxon, F., A simplified method of evaluating dose-effect experiments, J Pharmacol Exp Ther, 96(2):99-113 (1949).
[cited by applicant]
Loscher, W. et al., The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models, Epilepsy Res., 8:79-94 (1991).
[cited by applicant]
Pertwee, R. G., “The Pharmacology and Therapeutic Potential of Cannabidiol,” Cannabinoids, Chapter 3, DiMarzo, V. (Ed.), pp. 32-83 (2004).
[cited by applicant]
Swinyard, E. A. & Kupferberg, H. J., “Antiepileptic drugs: detection, quantification, and evaluation,” Federation Proceedings, 44(10):2629-2633 (1985).
[cited by applicant]
Ujávry, I. & Hanus, L., “Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy,” Cannabis and Cannabinoid Research, 1(1):90-101 (2016); doi:10.1089/can.2015.0012.
[cited by applicant]
Cited By (1)